Cover Image

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Todd J. Schwedt, Amaal J. Starling, Jessica Ailani, Andrew D. Hershey, Hope L. O'Brien, Elizabeth Seng, Adam S. Sprouse‐Blum, Scott B. Turner, Richard B. Lipton
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Headache: The Journal of Head and Face Pain
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update
by: Andrew C. Charles, et al.
Published: (2024)

The impact of headache intensity on speech in participants with migraine and acute post‐traumatic headache
by: Dani C. Smith, et al.
Published: (2024)

Remote electrical neuromodulation for reducing procedural pain in patients with chronic migraine receiving onabotulinumtoxinA injections: A randomized sham‐controlled study
by: Nan Cheng, et al.
Published: (2025)

The American Headache Society First Contact—Headache in Primary Care program: Current metrics, knowledge assessments, and direction for future initiatives
by: Mia T. Minen, et al.
Published: (2024)

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth
by: Carlyn Patterson Gentile, et al.
Published: (2024)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
by: Jessica Ailani, et al.
Published: (2026)

A history of abuse is associated with more severe migraine‐ and pain‐related disability: Results from the American Registry for Migraine Research
by: Meesha Trivedi, et al.
Published: (2024)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
by: Lawrence C. Newman, et al.
Published: (2025)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
by: Samantha C. Shao, et al.
Published: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
by: Delora E. Denney, et al.
Published: (2024)

Towards a standardized process of onboarding advanced practice providers into headache medicine practices in the United States: Expert consensus from the American Headache Society practice management committee
by: Calli Cook, et al.
Published: (2026)

Integrating gepants into clinical practice for the acute treatment of migraine
by: Richard B. Lipton, et al.
Published: (2026)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
by: Christopher C. Anderson, et al.
Published: (2024)

Today in headache medicine: Helpful analogies in headache medicine
by: Medha Tandon, et al.
Published: (2025)

Real‐world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program
by: Idris Demirsoy, et al.
Published: (2025)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
by: Jessica Ailani, et al.
Published: (2025)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
by: Jennifer Robblee, et al.
Published: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
by: Jennifer Robblee, et al.
Published: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
by: Richard B. Lipton, et al.
Published: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
by: Rikki Mangrum, et al.
Published: (2024)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
by: David Kudrow, et al.
Published: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
by: Kara S. Graves, et al.
Published: (2026)

Bridging old and new: The 2026 American Headache Society Annual Scientific Meeting
by: Mark J. Burish, et al.
Published: (2026)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
by: Chia‐Chun Chiang, et al.
Published: (2024)

Prevalence and burden of migraine in the United States: A systematic review
by: Fred Cohen, et al.
Published: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
by: Larry Charleston, et al.
Published: (2026)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
by: Jessica Ailani, et al.
Published: (2024)

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
by: Richard B. Lipton, et al.
Published: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
by: Graham A. McLeod, et al.
Published: (2025)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
by: Rebecca Lindsay, et al.
Published: (2024)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
by: Richard B. Lipton, et al.
Published: (2025)

Youth with high‐frequency headaches due to migraine are more vulnerable to non‐cephalic pain complaints
by: Brooke L. Reidy, et al.
Published: (2025)

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
by: Devin Teichrow, et al.
Published: (2026)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
by: Dawn C. Buse, et al.
Published: (2024)

Response to: Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics
by: Christina Murphy, et al.
Published: (2025)

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
by: David W. Dodick, et al.
Published: (2025)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
by: Susan Hutchinson, et al.
Published: (2026)

Headache activity associated with the 2024 North American eclipse
by: Timothy T. Houle, et al.
Published: (2024)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
by: Stephen D. Silberstein, et al.
Published: (2024)

What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United States
by: Fred Cohen, et al.
Published: (2025)